Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Phase III trials in oncology].

K Imadalou1, E Cvitkovic

  • 1CAC, Le Kremlin-Bicêtre.

Bulletin Du Cancer
|March 6, 1999
PubMed
Summary

Randomised trials are crucial for evaluating new oncology drugs. Strategies like evidence-based medicine and patient-controlled models can optimize trial design, potentially reducing patient numbers and costs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.

British journal of cancer·2010
Same author

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

British journal of cancer·2008
Same author

Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.

British journal of cancer·2007
Same author

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same author

Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2004

Area of Science:

  • Oncology
  • Clinical Trials
  • Evidence-Based Medicine

Context:

  • Randomised controlled trials (RCTs) are the gold standard for evaluating new oncology drugs.
  • Phase III trials require methodological rigor and adaptation to evidence-based medicine principles.
  • Alternative control models, such as patient-as-own-control, can supplement traditional randomization.

Purpose:

  • To emphasize methodological aspects of randomised trials in oncology.
  • To suggest strategies for optimizing phase III trials.
  • To explore context-specific adaptations and alternative control models for clinical experiments.

Summary:

  • The best context for assessing new oncology molecules is the randomised trial.
  • Strategies include adopting evidence-based medicine, context-specific endpoints, and patient-as-own-control models.
  • Restrictive eligibility criteria and other strategies can reduce patient numbers and trial duration/cost.

Impact:

  • Optimized trial designs can enhance the relevance and specificity of endpoints.
  • Reduced patient numbers and trial costs can accelerate drug development.
  • Improved trial methodologies contribute to more efficient oncology research and drug evaluation.

Related Experiment Videos